Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
30 Jul 2022
Historique:
received: 30 05 2021
accepted: 01 07 2022
entrez: 30 7 2022
pubmed: 31 7 2022
medline: 31 7 2022
Statut: epublish

Résumé

The development of a maternal HIV vaccine to synergize with current antiretroviral drug prophylaxis can overcome implementation challenges and further reduce mother-to-child transmission (MTCT) of HIV. Both the epitope-specificity and autologous neutralization capacity of maternal HIV envelope (Env)-specific antibodies have been implicated in decreased risk of MTCT of HIV. Our goal was to determine if heterologous HIV Env immunization of SHIV.C.CH505-infected, ART-suppressed female rhesus macaques (RMs) could boost autologous Env-specific antibodies. SHIV.C.CH505-infected female RMs (n = 12), began a daily ART regimen at 12 weeks post-infection (wpi), which was continued for 12 weeks. Starting 2 weeks after ART initiation, RMs received 3 monthly immunizations with HIV b.63521/1086.C gp120 or placebo (n = 6/group) vaccine with adjuvant STR8S-C. Compared to the placebo-immunized animals, Env-vaccinated, SHIV-infected RMs exhibited enhanced IgG binding, avidity, and ADCC responses against the vaccine immunogens and the autologous SHIV.C.CH505 Env. Notably, the Env-specific memory B cells elicited by heterologous vaccination were dominated by cells that recognized the SHIV.C.CH505 Env, the antigen of primary exposure. Thus, vaccination of SHIV-infected, ART-suppressed RMs with heterologous HIV Envs can augment multiple components of the antibody response against the Env antigen of primary exposure, suggesting antigenic seniority. Our results suggest that a universal maternal HIV vaccination regimen can be developed to leverage antigenic seniority in targeting the maternal autologous virus pool.

Identifiants

pubmed: 35907918
doi: 10.1038/s41541-022-00505-w
pii: 10.1038/s41541-022-00505-w
pmc: PMC9338948
doi:

Types de publication

Journal Article

Langues

eng

Pagination

87

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI131251
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI165080
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI117915
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 7P01AI117915-07
Organisme : NIAID NIH HHS
ID : R01 AI160607
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

J Virol. 1997 Mar;71(3):2233-40
pubmed: 9032358
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
J Virol. 2012 Apr;86(8):4129-38
pubmed: 22301151
J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):435-40
pubmed: 11981358
mSphere. 2018 Jan 10;3(1):
pubmed: 29359183
AIDS. 2010 Nov 27;24(18):2803-8
pubmed: 20962613
Top Antivir Med. 2015 May-Jun;23(2):80-4
pubmed: 26200707
J Infect Dis. 2000 Oct;182(4):1243-6
pubmed: 10979926
J Virol. 2020 Sep 15;94(19):
pubmed: 32669328
Curr HIV Res. 2009 Jan;7(1):2-11
pubmed: 19149549
J Virol. 1995 Feb;69(2):1001-12
pubmed: 7815476
J Infect Dis. 1998 May;177(5):1247-59
pubmed: 9593009
J Virol. 2002 Dec;76(24):12845-54
pubmed: 12438610
Proc Natl Acad Sci U S A. 1989 Oct;86(20):8055-8
pubmed: 2479014
Nat Commun. 2019 Apr 10;10(1):1660
pubmed: 30971703
mBio. 2020 Mar 10;11(2):
pubmed: 32156815
J Virol. 2014 Mar;88(6):3329-39
pubmed: 24390332
mBio. 2019 Sep 5;10(5):
pubmed: 31488511
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):594-599
pubmed: 31045647
Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4
pubmed: 31295427
J Virol. 2019 Jul 17;93(15):
pubmed: 31092583
J Virol. 2018 Sep 26;92(20):
pubmed: 30089691
J Immunol Methods. 2014 Feb;404:1-12
pubmed: 24316020
Immunol Rev. 2020 Jul;296(1):191-204
pubmed: 32666572
Blood. 1997 Aug 1;90(3):1109-14
pubmed: 9242542
PLoS Pathog. 2012;8(7):e1002802
pubmed: 22829765
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
Curr Opin HIV AIDS. 2007 Sep;2(5):367-74
pubmed: 19372914
J Virol. 2006 Jul;80(13):6525-33
pubmed: 16775339
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
Sci Transl Med. 2017 Sep 6;9(406):
pubmed: 28878010
Open Forum Infect Dis. 2016 May 19;3(2):ofw100
pubmed: 27419172
N Engl J Med. 2013 Nov 7;369(19):1828-35
pubmed: 24152233
J Virol. 2008 Apr;82(8):3952-70
pubmed: 18256145
AIDS. 1989 Sep;3(9):577-82
pubmed: 2551341
J Virol. 2019 Mar 21;93(7):
pubmed: 30651354
Curr HIV Res. 2013 Mar;11(2):144-59
pubmed: 23432490
Nat Commun. 2017 Nov 23;8(1):1732
pubmed: 29170366
Nature. 2016 Dec 8;540(7632):284-287
pubmed: 27841870
Clin Vaccine Immunol. 2017 Aug 4;24(8):
pubmed: 28566336
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
J Virol. 1999 Nov;73(11):8966-74
pubmed: 10516002
AIDS Rev. 2020 Oct 26;23(1):28-39
pubmed: 33105471
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Cell Host Microbe. 2015 Apr 8;17(4):500-6
pubmed: 25856755
BMC Infect Dis. 2019 Sep 16;19(Suppl 1):789
pubmed: 31526366
J Virol. 2017 Jul 12;91(15):
pubmed: 28539449
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
J Virol. 2020 Oct 14;94(21):
pubmed: 32817214
J Virol. 2015 Oct;89(19):9952-61
pubmed: 26202232
PLoS Pathog. 2012;8(6):e1002739
pubmed: 22719248
Trends Immunol. 2018 Jan;39(1):70-79
pubmed: 28867526
J Clin Invest. 1995 Feb;95(2):732-7
pubmed: 7860754
J Virol. 2020 Apr 16;94(9):
pubmed: 32075936
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
J Virol. 2003 Feb;77(4):2736-40
pubmed: 12552014
J Infect Dis. 2014 Nov 15;210(10):1529-38
pubmed: 24850788
J Virol. 2006 Sep;80(18):9217-25
pubmed: 16940533
J Virol. 2006 Jan;80(2):835-44
pubmed: 16378985
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
J Int AIDS Soc. 2017 Dec;20(4):
pubmed: 29282882
AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8
pubmed: 26150024
PLoS Pathog. 2018 Apr 19;14(4):e1006944
pubmed: 29672607
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
J Clin Invest. 2015 Jul 1;125(7):2702-6
pubmed: 26053661
Vaccine X. 2019 Jun 20;2:100029
pubmed: 31384744
Mol Biol Evol. 2010 Feb;27(2):221-4
pubmed: 19854763
mBio. 2017 Oct 24;8(5):
pubmed: 29066544
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
Nat Med. 2020 Apr;26(4):498-501
pubmed: 32235883
J Virol. 2021 Apr 12;95(9):
pubmed: 33568508

Auteurs

Ashley N Nelson (AN)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Maria Dennis (M)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Jesse F Mangold (JF)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Katherine Li (K)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Pooja T Saha (PT)

Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Kenneth Cronin (K)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Kaitlyn A Cross (KA)

Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Amit Kumar (A)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Riley J Mangan (RJ)

Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.

George M Shaw (GM)

Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Katharine J Bar (KJ)

Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Barton Haynes (B)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Anthony M Moody (AM)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

S Munir Alam (S)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Justin Pollara (J)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.

Michael G Hudgens (MG)

Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Koen K A Van Rompay (KKA)

California National Primate Research Center, University of California, Davis, CA, USA.

Kristina De Paris (K)

Department of Microbiology and Immunology and Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Sallie R Permar (SR)

Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA. sap4017@med.cornell.edu.

Classifications MeSH